| 摘要 |
Polysaccharides comprising at least 5 sialic acid residues per molecule are used to increase the circulation time of an active ingredient, for instance by decreasing the immunogenicity and/or increasing the stability in vivo of pharmaceutically active compounds. The pharmaceutically active compound may be a foreign protein which is covalently bound to the polysaccharide. Alternatively, the active compound may be associated with a drug delivery system (DDS), for instance a macro-molecular DDS or a particulate DDS, such as liposomes. The polysaccharide is usually a bacterial polysaccharide, e.g., a glycolipid or a derivative thereof, for instance polysaccharide B or E. Coli K1, N. meningitidis, Moraxella liquifaciens or Pasteurella aeroginosis, or K92 of E. Coli K92 strain.
|
